Asset Details
Do you wish to reserve the book?
GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study
Do you wish to request the book?
GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study
2018
Overview
Rationale
GR3027 is a novel small molecule GABA-A receptor-modulating steroid antagonist, which in non-clinical studies has shown promise for treatment of human disorders due to allosteric over-activation of GABA-A receptors by neurosteroids, such as allopregnanolone. We here studied its safety, pharmacokinetics, and ability to inhibit allopregnanolone effects in humans.
Methods
Safety and pharmacokinetics were studied in healthy adult males receiving ascending single or multiple oral GR3027 vs. placebo. GR3027-mediated reversal of allopregnanolone effect on maximal saccadic eye velocity (SEV), and self-rated somnolence was studied in a double-blind, placebo-controlled, three-part cross-over study in which 3 or 30 mg oral GR3027 preceded 0.05 mg/kg of i.v. allopregnanolone.
Results
GR3027 was well tolerated, adverse events were generally mild and transient, and no dose-limiting toxicity or grade 3 adverse events were observed up to the highest single (200 mg) or multiple (100 mg every 12 h for 5 days) doses. The maximum concentration (
C
max
) and systemic exposure (area under the plasma concentration-time curve from dose extrapolated to infinity [AUC
0–∞
] and/or AUC during the dosing interval [AUC
τ
]) varied linearly with dose; with dose-dependent accumulation ratios of 1.3–1.6. Allopregnanolone decreased SEV and induced somnolence in most, but not all subjects. By predefined analyses, 30 mg GR3027 significantly inhibited allopregnanolone-induced decrease in SEV (
p
= 0.03); 3 and 30 mg GR3027 non-significantly inhibited allopregnanolone-induced sedation. By post hoc analyses restricted to subjects with allopregnanolone-induced changes and the time period over which they occurred, GR3027 dose dependently inhibited allopregnanolone-induced decrease in SEV (
p
= 0.04 at 30 mg, non-significant at 3 mg) and allopregnanolone-induced sedation (
p
= 0.01/0.05 at 3/30 mg doses).
Conclusion
Oral GR3027 mitigates inhibition of brain function induced by allopregnanolone at doses which are clinically well tolerated and associated with linear pharmacokinetics.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Analysis
/ Biomedical and Life Sciences
/ Brain
/ Dose-Response Relationship, Drug
/ GABA
/ GABA-A Receptor Antagonists - pharmacology
/ GR3027
/ Humans
/ Male
/ Neurotransmitter Agents - antagonists & inhibitors
/ Neurotransmitter Agents - pharmacology
/ Pregnanolone - antagonists & inhibitors
/ Receptors, GABA-A - physiology
/ Sedation
/ Sleep
/ Toxicity
